All conditions

Pulmonary Hypertension

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1630
Trials on record
229
Recruiting now
8
Australian sites
19
Phase 3 trials
10
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Pulmonary Hypertension →

Get alerts when Pulmonary Hypertension trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Pulmonary Hypertension

Pulmonary hypertension is a condition where the blood pressure inside the arteries that carry blood from your heart to your lungs becomes too high. When this happens, the heart has to work much harder than normal to push blood through those vessels. Over time, this extra strain can cause the heart and lungs to work less efficiently. The condition is different from regular high blood pressure, which affects the arteries throughout the rest of your body. People sometimes find the diagnosis surprising because the symptoms — such as breathlessness, tiredness, and dizziness — can be easy to mistake for other, more common conditions.

In Australia, pulmonary hypertension is considered a rare disease, affecting a relatively small number of people. It can affect adults of any age, though it is more commonly diagnosed in women, and certain groups — including people with existing heart or lung conditions, connective tissue diseases like scleroderma, or a history of blood clots in the lungs — have a higher chance of developing it. Because the symptoms can develop gradually and are shared with many other conditions, it often takes some time before a diagnosis is reached.

Treatment in Australia is managed by specialist doctors, often at dedicated pulmonary hypertension centres in major hospitals. While there is currently no cure, there are a range of approved medications and therapies that aim to reduce symptoms, slow the progression of the condition, and help people maintain a reasonable quality of life. A care team typically includes cardiologists, respiratory physicians, and specialist nurses who work together to monitor the condition and adjust treatment over time. Support organisations, such as Pulmonary Hypertension Australia, can also be a valuable source of information and connection with others who share similar experiences.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Pulmonary Hypertension in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Pulmonary Hypertension

10 medicines listed on the PBS for Pulmonary Hypertension. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 10 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Ambrisentan Cipla Ambrisentan Pulmonary arterial hypertension (PAH) AU$1219.75 Authority required
Bosentan Bosentan RBX Pulmonary arterial hypertension (PAH) AU$117.53 Authority required
Epoprostenol Veletri Pulmonary arterial hypertension (PAH) AU$33.28 Authority required
Iloprost Ventavis Pulmonary arterial hypertension (PAH) AU$349.59 Authority required
Macitentan Opsumit Pulmonary arterial hypertension (PAH) AU$2299.25 Authority required
Macitentan + tadalafil Opsynvi Pulmonary arterial hypertension (PAH) AU$2552.08 Authority required
Riociguat Adempas Pulmonary arterial hypertension (PAH) AU$1631.82 Authority required
Selexipag Uptravi Pulmonary arterial hypertension (PAH) AU$3277.5 Authority required
Sildenafil Sildenafil Sandoz PHT 20 Pulmonary arterial hypertension (PAH) AU$95.81 Authority required
Tadalafil Tadalca, Tadalis 20 Pulmonary arterial hypertension (PAH) AU$475.54 Authority required
Riociguat Adempas thromboembolic pulmonary hypertension (CTEPH) AU$1631.82 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Pulmonary Hypertension currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Pulmonary Hypertension.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Pulmonary Hypertension by country. Australia is highlighted.

Showing the top 10 of 59 countries with trial sites.

Clinical trials for Pulmonary Hypertension

Showing 244 of 244 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT04175600 · Actelion Phase 3 · 32 countries Active, Not Recruiting
Active, Not Recruiting Phase 3 Est. completion 11 October 2024
🇦🇺 AU Belarus🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇳 CN🇨🇴 CO +24 more

**Who might be able to join this trial:** - Children aged 2 years old up to (but not including) 18 years old, who weigh at least 9 kilograms at the time of joining the trial - Children who have been diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the lungs), confirmed by a speci...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00367770 · Actelion Phase 4 · 11 countries Completed
Completed Phase 4 Est. completion 1 December 2005
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL +3 more

**Who might be able to join this trial:** - You completed the full 16-week BREATHE-5 clinical study (study code AC-052-405) and your pulmonary arterial hypertension (a type of high blood pressure in the lungs) was stable at the end of it. - If you are a woman, you are either not pregnant and cannot become pregnant (du...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT00380068 · Gilead Sciences Phase 3 · 3 countries Completed
Completed Phase 3 Est. completion 1 July 2008
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) caused by one of several specific conditions, including: idiopathic or familial pulmonary arterial hypertension (PAH), PAH linked to connective tissue di...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00810693 · Bayer Phase 3 · 30 countries Completed
Completed Phase 3 Est. completion 14 May 2012
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ +22 more

Who might be able to join this trial: - Men and women who have been diagnosed with pulmonary arterial hypertension (high blood pressure in the lungs) that is causing symptoms, including types caused by unknown reasons, family history, connective tissue diseases, certain heart defects present from birth, high pressure i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01106014 · Actelion Phase 3 · 39 countries Completed
Completed Phase 3 Est. completion 1 April 2014
🇦🇷 AR🇦🇺 AU🇦🇹 AT Belarus🇧🇪 BE🇨🇦 CA🇨🇱 CL🇨🇳 CN +31 more

**Who might be able to join this trial:** - You are between 18 and 75 years old (male or female) and have symptoms of pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs - Your PAH falls into one of these specific categories: no known cause (idiopathic), inherited (runs in the f...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01338415 · Actelion Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 13 August 2014
🇦🇺 AU Belarus🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇳 IN +10 more

**Who might be able to join this trial:** - You completed the previous related study (called FUTURE 3 / AC-052-373), or left that study early because your pulmonary arterial hypertension (PAH) got worse — as long as the study medication (bosentan) was not stopped permanently. - You tolerated the children's form of bose...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02279160 · United Therapeutics Phase 2 · 9 countries Completed
Completed Phase 2 Est. completion 1 June 2017
🇦🇺 AU🇧🇬 BG🇨🇿 CZ🇭🇺 HU🇵🇱 PL🇷🇴 RO🇷🇸 RS🇪🇸 ES +1 more

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You have been diagnosed with a specific type of pulmonary arterial hypertension (high blood pressure in the lungs) known as WHO Group 1 PAH, which includes idiopathic (unknown cause), heritable (genetic), drug- or toxin-relat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02279745 · United Therapeutics Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 29 March 2021
🇦🇺 AU🇧🇬 BG🇨🇿 CZ🇭🇺 HU🇵🇱 PL🇷🇴 RO🇷🇸 RS🇸🇰 SK +2 more

**Who might be able to join this trial:** - You signed and dated a consent form agreeing to take part in the study. - You were willing and able to attend scheduled visits, follow the treatment plan, and complete all required tests and procedures for a long-term study. - If you are a woman, you were not pregnant or bre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02558231 · Actelion Phase 3 · 15 countries Completed
Completed Phase 3 Est. completion 29 August 2019
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇪 IE +7 more

**Who might be able to join this trial:** - You are aged 18 to 75 years old - You have been diagnosed with pulmonary arterial hypertension (high blood pressure in the lungs) less than 6 months before joining the study - You have had a specific heart and lung pressure test (called a right heart catheterization) within...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04576988 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc.... Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 26 August 2022
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE +13 more

**Who might be able to join this trial:** - Adults aged 18 or older - People who have had a right heart catheterization (a procedure to measure blood pressure in the lungs) at any point before the screening period, confirming a diagnosis of pulmonary arterial hypertension (PAH) — a condition where blood pressure in th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05587712 · Merck Sharp & Dohme LLC Phase 2 · 12 countries Recruiting
Recruiting Phase 2 Est. completion 21 September 2028
🇦🇺 AU🇨🇴 CO🇫🇷 FR🇩🇪 DE🇮🇱 IL🇳🇱 NL🇵🇱 PL🇿🇦 ZA +4 more

**Who might be able to join this trial:** - You have been diagnosed with pulmonary arterial hypertension (PAH) — high blood pressure in the lungs — confirmed by a past heart procedure called a right heart catheterization, and your PAH falls into one of these specific types: inherited, caused by a drug or toxin, relate...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06649110 · Novartis Pharmaceuticals Phase 2 · 18 countries Recruiting
Recruiting Phase 2 Est. completion 29 November 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇬🇷 GR +10 more

**Who might be able to join this trial:** **Part A (Healthy Volunteer Phase):** - People who are male, or female and not able to become pregnant, and are in general good health **Part B (Patient Phase):** - People who have a confirmed diagnosis of pulmonary arterial hypertension (a type of high blood pressure affecti...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07073820 · Pfizer Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 18 July 2028
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇬🇷 GR +6 more

**Who might be able to join this trial:** - People who were 18 years of age or older when they entered the previous related study, and who completed the full required treatment period with PF-07868469 along with all assessments at the end of that study. - People who are willing and able to attend all scheduled visits,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07175038 · AllRock Bio, Inc. Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇱🇻 LV🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are able to give written consent before any study procedures begin - People who have been diagnosed with pulmonary arterial hypertension (high blood pressure in the lungs) or pulmonary hypertension related to interstitial lung disease (ILD-PH), co...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07179380 · Insmed Incorporated Phase 3 · 23 countries Recruiting
Recruiting Phase 3 Est. completion 30 December 2028
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇬🇪 GE +15 more

**Who might be able to join this trial:** - You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) related to a scarring lung disease, such as idiopathic interstitial pneumonia, chronic hypersensitivity pneumonitis, connective tissue disease-associated lung disease, or combined pulmonar...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07218029 · Merck Sharp & Dohme LLC Phase 3 · 26 countries Recruiting
Recruiting Phase 3 Est. completion 7 December 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇴 CO🇭🇷 HR🇨🇿 CZ +18 more

**Who might be able to join this trial:** - People who have fully completed a previous clinical study of sotatercept for pulmonary arterial hypertension (a type of high blood pressure affecting the lungs), including all of that study's requirements, and who did not leave that study early - People who are willing and ab...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07318597 · Regeneron Pharmaceuticals Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 27 February 2028
🇦🇺 AU🇧🇪 BE🇫🇷 FR🇩🇪 DE🇱🇻 LV🇵🇱 PL🇰🇷 KR🇪🇸 ES +2 more

**Who might be able to join this trial:** - People who have been formally diagnosed with Pulmonary Arterial Hypertension (PAH), specifically classified as Group 1 pulmonary hypertension under international medical guidelines - People whose PAH causes slight to moderate limitations on their daily physical activities (k...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07623525 · Diagonal Therapeutics, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇦🇺 AU🇳🇿 NZ

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with HHT (Hereditary Haemorrhagic Telangiectasia) either through medical assessment or genetic testing - People whose liver and kidneys are functioning at an adequate level - (For Part B of the trial) People with HHT who experience...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01392495 · Novartis Pharmaceuticals Phase 3 · 7 countries Terminated
Terminated Phase 3 Est. completion 1 March 2014
🇦🇺 AU🇧🇪 BE🇩🇪 DE🇮🇹 IT🇱🇹 LT🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You must have fully completed the previous related clinical trial (called CQTI571A2102), including all final assessments at the end of that study - You must have met the eligibility requirements for that previous trial and must not have been removed from it for safety reasons Wh...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02138825 · Bayer Phase 2 · 21 countries Terminated
Terminated Phase 2 Est. completion 5 May 2016
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇴 CO🇩🇰 DK🇫🇷 FR🇩🇪 DE +13 more

**Who might be able to join this trial:** - You are between 18 and 80 years old - You have been diagnosed with, or are suspected of having, one of several specific types of idiopathic interstitial pneumonia (a group of lung conditions where the cause of scarring or inflammation is unknown) — including conditions such...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03689244 · Actelion Phase 3 · 31 countries Terminated
Terminated Phase 3 Est. completion 7 June 2022
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇳 CN +23 more

**Who might be able to join this trial:** - You are willing and able to sign and date a consent form agreeing to take part - You are between 18 and 85 years old (or the legal age of consent in your country) at the time of your first screening visit - You have been diagnosed with a type of high blood pressure in the lu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07473700 · Tectonic Operating Company, Inc. Phase 2 · 5 countries Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 21 November 2027
🇵🇱 PL🇷🇴 RO🇷🇸 RS🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of scarring lung disease (ILD), confirmed by a chest CT scan taken within the last 12 months, showing that at least 10% of your lung tissue is affected by scarring. - Your lung capacity (how much air your lungs can hold) falls within a spe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07666841 · Tel-Aviv Sourasky Medical Center Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 July 2028
🇮🇱 IL

**Who might be able to join this trial:** - You have been diagnosed with COPD and your lung function is significantly reduced, or you were hospitalised due to COPD in the past year, or you had two or more moderate COPD flare-ups in the past year. - You have been diagnosed with a scarring or stiffening lung disease (in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00710177 · Medical College of Wisconsin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - Babies born at 34 weeks of pregnancy or later who have been diagnosed with persistent pulmonary hypertension of the newborn (a condition where blood pressure in the lungs remains high after birth) - Babies born at 34 weeks of pregnancy or later who are healthy and have no known c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01347216 · Technische Universität Dresden Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇧🇪 BE🇩🇪 DE🇮🇹 IT🇨🇭 CH

Who might be able to join this trial: - People of any age are welcome to participate. - You must be willing and able to give written consent to take part in the study. - You must have been diagnosed with pulmonary hypertension (high blood pressure in the lungs), which can include several types: the form with no known c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01501838 · Hospital Italiano de Buenos Aires Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇦🇷 AR

**Who might be able to join this trial:** - You have been diagnosed with a specific type of high blood pressure in the lungs (called pulmonary arterial hypertension, or PAH, Group 1), confirmed by certain measurements taken during a heart catheter procedure showing abnormal pressure and blood flow resistance in the lun...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01607502 · Medical University of Graz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇦🇹 AT

Who might be able to join this trial: - People who have been diagnosed with pulmonary hypertension (high blood pressure in the arteries of the lungs) - People who are considered at risk of developing pulmonary hypertension - People who have symptoms that may possibly be caused by pulmonary hypertension - People who hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01712620 · National Institutes of Health Clinical Center (CC) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of pulmonary hypertension (high blood pressure in the lungs) called WHO Group 1, confirmed by a heart catheter test showing specific pressure and resistance measurements in your lungs - You are either not taking any medication for...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01730092 · National Institutes of Health Clinical Center (CC) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇺🇸 US

**Who might be able to join this trial:** **For people with confirmed or suspected pulmonary arterial hypertension (PAH):** - Adults aged 18 or older who have been diagnosed with, or are suspected to have, a specific type of high blood pressure in the lungs called Group 1 pulmonary hypertension - People whose heart ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01884051 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2032
🇺🇸 US

Who might be able to join this trial: **Project 1 (includes a skin biopsy component):** - People diagnosed with a type of high blood pressure affecting the lungs (either idiopathic, heritable, or associated with another condition), or family members of someone with one of these diagnoses - People aged 0 to 90 years ol...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02061787 · Chinese Pulmonary Vascular Disease Research Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 September 2030
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the lungs), classified as WHO Group 1 - People diagnosed with chronic thromboembolic pulmonary hypertension (high blood pressure in the lungs caused by long-term blood clots) - People d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02249923 · New York Medical College Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - Your pulmonary hypertension (high blood pressure in the lungs) must have started before you were 18 years old. - The person giving consent for participation must be able to read either Spanish or English. - You, your parent, or your legal guardian must be willing and able to give...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02691689 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇧🇪 BE

Who might be able to join this trial: - People who have previously been diagnosed with a specific type of hole in the heart, either between the upper chambers (called a secundum atrial septal defect) or between the lower chambers (called a ventricular septal defect), whether or not it has been repaired - People who hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02966665 · Russell Richardson Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - Healthy adults between 18 and 30 years old with no health conditions that would affect their participation - Healthy adults aged 65 or older with no health conditions that would affect their participation - People who are already scheduled to have a routine coronary angiogra...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02986087 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - The baby has been diagnosed with an isolated congenital diaphragmatic hernia (a hole in the diaphragm) with the liver pushed up into the chest cavity. - Ultrasound measurements show the baby's lungs are severely underdeveloped (a specific measurement called O/E LHR is below...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03138863 · Rodrigo Ruano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - The pregnancy involves only one baby (not twins or more) - The baby's chromosomes have been confirmed as normal through lab testing (a specific rapid test result may be acceptable if the pregnancy is past 26 weeks) - The baby has been diagnosed with a left-sided congenital d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03269630 · Louisiana State University Health Sciences Center in New Orleans Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) and are being seen at the Comprehensive Pulmonary Hypertension Center - People who have been diagnosed with systemic sclerosis (a connective tissue disease that can affect the skin and o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03854071 · Sheffield Teaching Hospitals NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇬🇧 GB

Who might be able to join this trial: - Healthy volunteers between the ages of 20 and 80, recruited from Sheffield Teaching Hospitals staff members - People between the ages of 20 and 80 who have suspected or known heart disease (across one of five patient groups) - People who are able to provide written consent to par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03959748 · Polish Cardiology Association Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2023
🇵🇱 PL

Who might be able to join this trial: - People diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the lungs) or chronic thromboembolic pulmonary hypertension (lung high blood pressure caused by blood clots) after 1st March 2018, who are older than 3 months at the time of joining the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03978377 · University Medical Center Groningen Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇧🇪 BE🇳🇱 NL🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with oesophageal cancer in the middle or lower part of the oesophagus, OR a type of lung cancer (non-small cell lung cancer at certain stages, including some cases with a limited number of brain tumours treatable by surgery or targeted radiation, or sm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03980717 · Michael A Belfort Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - The patient must be a pregnant woman between 18 and 45 years of age - The pregnancy must be a single baby (not twins or more) - The baby must be between 28 weeks and 31 weeks and 6 days of pregnancy at the time of assessment - The baby must have a confirmed severe diagnosis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04062565 · University of Arizona Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2025
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of pulmonary arterial hypertension (high blood pressure in the lungs) classified as WHO Category I - Testing of your heart (via a procedure called right heart catheterization) has shown that the pressure in your pulmonary artery i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04071327 · Pulmonary Hypertension Association, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

Who might be able to join this trial: - People of any age are welcome to participate. - Written consent to take part in the trial must be provided (for children, a parent or guardian would typically provide this). - People who have been diagnosed with pulmonary arterial hypertension (PAH), chronic thromboembolic pulmon...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04078243 · Sheffield Teaching Hospitals NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 January 2028
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with pulmonary hypertension (high blood pressure in the lungs), in any of the main types (Groups I, II, III, or IV) - People who are 18 years of age or older - People whose kidneys are functioning above a certain level, based on a blood test re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04145024 · University of Giessen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2035
🇩🇪 DE

"Who might be able to join this trial: - People who have had a right heart catheterization procedure to diagnose pulmonary hypertension (a type of high blood pressure affecting the lungs and heart) at the Giessen site. Who may not be able to join: - People who have not provided their signed agreement (informed consent...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04206852 · Chinese Pulmonary Vascular Disease Research Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a condition called CTEPH (chronic thromboembolic pulmonary hypertension), meaning old blood clots are causing high blood pressure in the lungs, confirmed by specific scans (such as a VQ scan, CT scan, or MRI of the lungs) - Your blood pressure in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04467333 · University of Giessen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 January 2026
🇩🇪 DE

Who might be able to join this trial: - You have lung cancer and are being treated or seen at the University of Giessen Lung Cancer Center. Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm with trial site). Important: Always verify eligibility with the trial site...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04484675 · Zagazig University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 10 May 2025
🇪🇬 EG

**Who might be able to join this trial:** - You are scheduled to have mitral valve (heart valve) surgery using a heart-lung bypass machine - Before your surgery, a special ultrasound test of your heart showed that the blood pressure in your lung arteries is significantly high (at or above a certain level measured durin...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04555161 · Aria CV, Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇺🇸 US

**Who might be able to join this trial:** **Criteria that apply to all groups:** - Adults aged 18 or older. - People whose tests show the average blood pressure in the main lung artery is above a certain level (above 25 mmHg). - People whose heart tests show the right side of the heart is not pumping as well as it sho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04624490 · Mario Castro, MD, MPH Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 26 October 2028
🇺🇸 US

**Who might be able to join this trial:** *If you are a healthy volunteer:* - You have no diagnosed lung conditions - You are able to read and understand English or Spanish *If you have a lung condition:* - A doctor has diagnosed you with a lung or breathing problem - Your lung condition has not gotten worse in the p...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04654650 · Universitätsklinikum Hamburg-Eppendorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 January 2041
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs), classified as group 1 through 5 - You are able to understand and agree to take part in the study by giving your consent Who may not be able to join: - You have decided to withdraw your agreem...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04756076 · Jiapeng Huang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pulmonary hypertension (high blood pressure in the arteries of the lungs) - People who agree to follow the study's rules and procedures - Healthy volunteers (people without pulmonary hypertension may also be invited to take part as a compar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04778046 · Bastiaan Driehuys Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who are currently on the lung transplant waiting list at Duke University Medical Center - People who have been found through a specific heart catheter test (called a right heart catheterization) to have elevated pressure in the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04808596 · University of Kansas Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a patient at TUKHS (The University of Kansas Health System) or have already agreed to take part in a study approved by the University of Kansas Medical Center's research oversight program. - You have been diagnosed with pulmonary hypertension (high blood pressure in t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04898114 · Sohag University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2025
🇪🇬 EG

**Who might be able to join this trial:** - The baby was born at 36 weeks of pregnancy or later (not very premature). - The baby weighs between 2.5 kg and 4 kg at birth. - The baby is between 6 and 72 hours old at the time of joining the trial. - The baby has been diagnosed with a specific lung blood pressure condition...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04901884 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 years or older - People who have a chest tumour that has been confirmed by biopsy or other clinical assessment, and is planned to be treated with radiation therapy (with or without chemotherapy) - People whose planned radiation treatment is expected to expose...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04993612 · Ayham Daher Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇩🇪 DE

Who might be able to join this trial: - You have a clear medical reason why your doctor has recommended a right heart catheterization procedure. - You are older than 18 years of age. - You are willing and able to sign a consent form agreeing to take part in the study. Who may not be able to join: - You are not fully a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05110066 · University of Aarhus Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇩🇰 DK🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with chronic thromboembolic pulmonary hypertension (a type of high blood pressure in the lungs caused by blood clots) according to current European medical guidelines - People whose medical team has determined they are suitable candidates for both s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05140525 · Dr Sudarshan Rajagopal Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), a condition where blood clots cause high blood pressure in the lungs - People who are not suitable for surgery to remove the blood clots (calle...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05179876 · Actelion Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 31 January 2027
Belarus🇧🇪 BE🇧🇬 BG🇨🇳 CN🇭🇺 HU🇵🇱 PL🇷🇺 RU🇿🇦 ZA +5 more

Who might be able to join this trial: - People who have signed a consent form (or had their legal representative sign one) showing they understand the study and are willing to take part. - People who were taking oral macitentan, selexipag, or a fixed-dose combination of macitentan 10mg and tadalafil 40mg at the end of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05201144 · University of Utah Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2026
🇺🇸 US

**Who might be able to join this trial:** - The baby must be a newborn admitted to the Phoenix Children's Hospital NICU (Neonatal Intensive Care Unit) - The baby must have been diagnosed with congenital diaphragmatic hernia (CDH), which is a condition where there is a hole in the diaphragm (the muscle separating the ch...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05213676 · The University of Texas Health Science Center, Houston Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 October 2030
🇺🇸 US

Who might be able to join this trial: - Newborns who are born alive and diagnosed with a type of diaphragmatic hernia called a Bochdalek hernia (located on either the left or right side of the diaphragm) - Babies who have other additional health conditions or abnormalities alongside the hernia may still be considered f...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05286814 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** **Criteria that apply to all groups:** - People who have been diagnosed with one of the following cancers: metastatic colorectal cancer (bowel cancer that has spread), intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver), or adrenocortical carcinoma (a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05311072 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a condition called chronic thromboembolic pulmonary hypertension (CTEPH) — a type of high blood pressure in the lungs caused by old blood clots - People who are willing to agree to take part and sign a consent form - People whose diagnosis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05329714 · University of Giessen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2050
🇩🇪 DE

"Who might be able to join this trial: - People who have been clinically diagnosed with Pulmonary Hypertension (a condition where blood pressure in the lungs is abnormally high) Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm with trial site) Important: Always ve...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05340023 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇫🇷 FR

Who might be able to join this trial: - People who are suspected of having a condition called Chronic Thromboembolic Pulmonary Hypertension (CTEPH), where old blood clots cause high blood pressure in the lungs, based on results from specific breathing/heart scans that are consistent with this diagnosis (following Frenc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05368467 · Nanjing First Hospital, Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with pulmonary hypertension (PH), whether recently or in the past. - People who have had a specific heart procedure called a right heart catheterization that measured the blood pressure in their pulmonary artery (the artery going to the lungs) a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05372263 · China National Center for Cardiovascular Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇨🇳 CN

Who might be able to join this trial: - You are between 3 months and 85 years old (any sex is welcome) - A heart procedure called a right heart catheterization has shown that the blood pressure in your lungs is high, with specific measurements meeting set thresholds (confirm with trial site) - You have been diagnosed w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05442671 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Be between 8 and 18 years old - Have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) belonging to one of four specific types (types 1, 2, 3, or 4 as defined by the World Health Organization) - Have a mild level of illness — specifically WHO funct...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05452889 · Stephen Y. Chan Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 75 years old - You have been diagnosed with a specific type of pulmonary hypertension (high blood pressure in the lungs) confirmed by a heart procedure called a right heart catheterization, OR you have scleroderma (a connective tissue disease) without pulmo...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05462574 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People diagnosed with a specific type of pulmonary arterial hypertension (high blood pressure in the lungs) that is either idiopathic (no known cause), inherited, linked to a connective tissue disease, or caused by a drug or toxin, as def...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05464095 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 May 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older. - People diagnosed with pulmonary arterial hypertension (PAH) — a condition causing high blood pressure in the lungs — where the cause is unknown (idiopathic), inherited (heritable), linked to connective tissue disease, caused by certain drugs or toxins,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05553223 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with moderate-to-severe COPD (a chronic lung condition) - You have not smoked for more than 6 months - Your COPD has been stable, meaning you have not had a flare-up or worsening of symptoms in the last 6 weeks - Your lung function test results fall wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05566002 · Chinese Pulmonary Vascular Disease Research Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have previously had a chest X-ray, heart tracing (ECG), heart ultrasound (echocardiogram), other routine tests, and a right heart catheterisation (a procedure to measure pressure inside the heart) carried out at Fuwai Hospital,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05584722 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

Who might be able to join this trial: - You are between 15 and 80 years old - You have been diagnosed with pulmonary arterial hypertension (PAH) that has no known cause or runs in your family, confirmed by standard medical tests - You carry a BMPR2 gene mutation but are otherwise healthy, with normal heart and lung pre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05610631 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇭 CH

"Who might be able to join this trial: - You have been diagnosed with pulmonary hypertension (high blood pressure in the arteries of the lungs) Who may not be able to join: - No exclusion criteria have been listed for this trial (confirm with trial site) Important: Always verify eligibility with the trial site direct...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05611268 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2024
🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with Eisenmenger syndrome and your doctor has rated your symptoms as Class II, III, or IV (a scale used to measure how much your condition affects daily life) - You may or may not currently be taking warfarin (a blood-thinning tablet) — both are accept...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05636397 · The Hospital for Sick Children Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇦 CA

**Who might be able to join this trial:** **Group 1 – Babies with lung disease and/or high blood pressure in the lungs (BPD±PH):** - The baby was born at 30 weeks of pregnancy or earlier - The baby has reached at least 32 weeks of corrected age (counting from the original due date) - For babies who also have high bloo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05638269 · Zhujiang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 75 years old - You have been living in the same province as the hospital for the past three years - You have been officially diagnosed by a doctor with one of the specific conditions this trial is studying (confirm with trial site for which conditions quali...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05665556 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇲🇽 MX

**Who might be able to join this trial:** - People who have been diagnosed with Group I Pulmonary Arterial Hypertension (a type of high blood pressure in the lungs) that is linked to a connective tissue disease (conditions that affect the body's connective tissues, such as lupus, scleroderma, or rheumatoid arthritis)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05678062 · University of Cape Town Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇿🇦 ZA

Who might be able to join this trial: - People who have been diagnosed with preeclampsia (a pregnancy complication involving high blood pressure) and have also had new tonic-clonic seizures (a type of seizure involving stiffening and jerking of the body), as defined by the American College of Obstetricians and Gynecolo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05679206 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇭 CH

**Who might be able to join this trial:** - People who are older than 16 years of age - People who have given consent to participate, or for whom a consent waiver has been granted according to the relevant guidelines - People who have been diagnosed with preeclampsia, which is defined as new high blood pressure (above...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05703191 · Novlead Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2025
🇨🇳 CN

Who might be able to join this trial: - The treating clinician has determined that the patient may benefit from inhaled nitric oxide and has chosen to use the specific Nitric Oxide Generator and Delivery System being studied. - The patient is admitted to the Neonatology Department (newborn care unit) at the participati...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05719415 · Jewish General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2028
🇨🇦 CA

"Who might be able to join this trial: - People who have chronic thromboembolic pulmonary hypertension (a condition where old blood clots block the arteries in the lungs, causing high blood pressure in those arteries) and who a doctor has determined are suitable for a procedure called balloon pulmonary angioplasty (whe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05745961 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2025
🇬🇧 GB

**Who might be able to join this trial:** - People who are able to give written consent before any study procedures begin. - People who are able to lie comfortably on their back for up to 90 minutes at a time. - Women who could become pregnant may be eligible if a sensitive pregnancy test comes back negative and a hig...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05746039 · University of Pennsylvania Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following lung conditions: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease (COPD), or pulmonary hypertension - You are older than 18 years of age - Your Body Mass Index (BMI) — a measure of body weight rela...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05798923 · OrphAI Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 80 years old (those over 70 would need approval from a medical monitor overseeing the trial) - People who have been diagnosed with pulmonary hypertension associated with interstitial lung disease (PH-ILD), confirmed by a CT scan within the past year, linked...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05825417 · Sheffield Teaching Hospitals NHS Foundation Trust Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 January 2027
🇬🇧 GB

**Who might be able to join this trial:** - You are between 18 and 80 years old - You are able to understand and sign a consent form agreeing to take part - You have been diagnosed with pulmonary arterial hypertension (high blood pressure in the lungs) that is either inherited, has no known cause, or was caused by cer...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05841615 · The First Affiliated Hospital of Xiamen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People whose blood pressure readings are high — either at least 140/90 mmHg in a clinic setting, or an average of at least 135/85 mmHg over a 24-hour monitoring period - People whose ECG (heart tracing) shows a heart rhythm condition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05843500 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been referred with a condition called CTED or CTEPH — these are lung conditions caused by old blood clots that have not fully cleared, which can make the heart and lungs work harder and cause breathing difficulties. - People whose diagnosis is supported by at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05844462 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 to 84 years old at the time of joining the trial - People experiencing shortness of breath classified as moderate to very severe (WHO functional class II to IV) - People who have been diagnosed with severe pulmonary hypertension (high blood pressure in the lun...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05873387 · Eko Devices, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇺🇸 US

Who might be able to join this trial: - Adults over 18 years old who have been referred by their doctor for a complete 2-dimensional echocardiogram (a detailed ultrasound of the heart) or a right heart catheterization (a procedure to check how well the heart is pumping) Who may not be able to join: - People who are on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05896579 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with COPD, confirmed by a specific breathing test showing airflow limitation (FEV1/FVC ratio below 0.7) - People who are 40 years of age or older Who may not be able to join: - People who had a COPD flare-up or worsening of symptoms in the 3 months...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05903001 · RWTH Aachen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with one of these lung conditions: COPD, bronchial asthma, pulmonary fibrosis, or pulmonary hypertension - You are 18 years old or older - You are able to understand what the study involves and can follow the instructions given to you - You are legally...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05935605 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been referred to a hospital for a procedure called a right heart catheterization (a test that measures pressures inside your heart) for any reason. - You have been diagnosed with heart failure where the heart muscle still pumps normally (sometimes called HFpEF), wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05937854 · VA Office of Research and Development Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are seen as outpatients and have been diagnosed with COPD, shown by breathing test results or evidence of emphysema on a chest scan confirmed by a study doctor. - People who have evidence of raised pressure in the arteries of the lungs, shown by at least one of th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05958901 · The First Affiliated Hospital of Guangzhou Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People whose average blood pressure in the lung arteries is higher than 25mmHg while at rest, or higher than 30mmHg during exercise. - People who are willing and able to follow the study requirements, including attending study visits over a 5-year period, and who have signed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05967299 · National Heart, Lung, and Blood Institute (NHLBI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You are willing to follow all study procedures and are available for the full duration of the study - You are male or female, between 18 and 60 years old (inclusive) - You are in good general health based on your medical history - If you are a woman who could become pregnant,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06038630 · Bastiaan Driehuys Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** **Healthy volunteers may be eligible if they:** - Are over 18 years old and are being seen as an outpatient - Are willing and able to give informed consent and follow the study schedule - Have no diagnosed lung conditions - Have not smoked in the past 5 years - Have a smoking...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06053580 · University of Washington Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 80 years old (male or female) - You have been diagnosed with a specific type of high blood pressure in the lungs called WHO Group 1 Pulmonary Arterial Hypertension - Your symptoms fall into a moderate to severe category based on how much your condition limi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06081881 · Ester Ashraf Faried Beshay Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with an acute pulmonary embolism (a blood clot in the lungs) - You are between 18 and 80 years old - Your condition has been assessed using a scoring tool (called PESI or sPESI) and your score falls into a moderate-to-high risk category (confirm with trial...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06090838 · Amsterdam UMC, location VUmc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇳🇱 NL

Who might be able to join this trial: - People who had an acute blood clot in the lungs (pulmonary embolism) at least 3 months before joining the trial, which was properly treated - People who still have ongoing breathing or activity limitations, rated as a level 2 or higher on a standard medical scale (NYHA class ≥2)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06099015 · Lifetech Scientific (Shenzhen) Co., Ltd. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇩🇪 DE🇮🇹 IT Turkey (Türkiye)

Who might be able to join this trial: - People aged 18 to 85 years old - People with a life expectancy of more than one year - People who need a procedure to block blood flow in an artery or vein in the peripheral vascular system (the blood vessels outside the heart and brain) - People whose treatment site allows a sma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06104228 · Bastiaan Driehuys Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** *For Arm 1 (Idiopathic Pulmonary Arterial Hypertension – IPAH):* - You are between 18 and 75 years old - Your pulmonary arterial hypertension (high blood pressure in the lungs) affects your daily activities at a moderate level (confirm with trial site for exact classification)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06105242 · Intermountain Health Care, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with a specific type of pulmonary hypertension called CTEPH (chronic thromboembolic pulmonary hypertension), following current medical guidelines - People who had a heart ultrasound (echocardiogram) taken within 3 months of their di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06129240 · Liquidia Technologies, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇺🇸 US

**Who might be able to join this trial:** **Cohort A (Group A):** - Adults between 18 and 80 years old - Have been diagnosed with a specific type of pulmonary hypertension linked to lung disease (called WHO Group 3 PH-ILD), confirmed by a chest CT scan showing widespread lung disease, plus specific pressure measuremen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06135909 · Chinese Pulmonary Vascular Disease Research Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - You are willing and able to sign a consent form agreeing to take part in the study - You are between 18 and 85 years old - You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) and are currently using, or planning to use, specific medications for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06286891 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇧🇷 BR

Who might be able to join this trial: - People who are 18 years of age or older - People of any gender - People who are scheduled for a planned (non-emergency) pulmonary endarterectomy surgery (a surgery to remove blood clots from the arteries in the lungs) - People who do not have any thinking or physical movement dif...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06291389 · Al-Azhar University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2026
🇪🇬 EG

Who might be able to join this trial: - People between 20 and 50 years old - People who have been classified as ASA Physical Status Class I, meaning generally healthy with no serious medical conditions (confirm with trial site) - People scheduled to have an abdominoplasty (tummy tuck) operation Who may not be able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06299436 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2029
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 90 years old - People who have been diagnosed with heart failure where the heart is not pumping as strongly as it should (with a specific measurement of heart pumping function at or below a certain level) - People whose blood-thinning medication (either a ty...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06317805 · AOP Orphan Pharmaceuticals AG Phase 4 · 10 countries Recruiting
Recruiting Phase 4 Est. completion 1 June 2027
🇦🇹 AT🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇹 IT🇵🇱 PL🇵🇹 PT +2 more

**Who might be able to join this trial:** - You are aged 18 to 70 years old - You have been diagnosed with pulmonary arterial hypertension (PAH) — a type of high blood pressure affecting the lungs — and have not yet received any treatment for it - Your PAH falls into one of these specific types: the cause is unknown (...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06331208 · Institute for Clinical and Experimental Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇿 CZ

**Who might be able to join this trial:** **Heart Failure group:** - You are older than 18 years - You are willing and able to sign a consent form to participate - Your heart's pumping strength (the amount of blood pumped out with each beat) is below 50% - You have been diagnosed with heart failure for more than 6 mon...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06336798 · Emory University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a consent form and follow all study procedures for the full duration of the trial - People who have been confirmed to have pulmonary hypertension (high blood pressure in the lungs) caused by a chronic lung disease, based on a specific...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06350032 · AOP Orphan Pharmaceuticals AG Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 1 November 2028
🇦🇹 AT🇫🇷 FR🇭🇺 HU🇸🇰 SK🇪🇸 ES

Who might be able to join this trial: - A parent or legal guardian must have signed a consent form, and children old enough to do so must have given their written agreement to take part - Children from newborn up to (but not including) 18 years of age at the time consent was signed - Children who have been diagnosed wi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06351345 · Bastiaan Driehuys Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 4 February 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 75 years old who are being treated as outpatients (not currently hospitalised), of any gender - People diagnosed with a specific type of high blood pressure in the lungs called pulmonary arterial hypertension (Group 1 PAH), confirmed by a procedure that...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06362382 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 60 years old - People who have been diagnosed with pulmonary hypertension (high blood pressure in the lungs), confirmed by a right heart catheterization test showing specific pressure and resistance readings - People with one of three specific type...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06373289 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 July 2029
🇺🇸 US

"Who might be able to join this trial: - Your baby was born between 22 weeks and 0 days and 31 weeks and 6 days of pregnancy (considered very premature) - Your baby has been diagnosed with high blood pressure in the lungs (pulmonary hypertension), confirmed by an ultrasound of the heart showing specific signs of this c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06374277 · University of Tennessee Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are covered by Medicaid or have no health insurance, and you are currently admitted to the hospital - You are 21 years of age or older - You have been diagnosed with 2 or more ongoing (long-term) health conditions, OR you are currently taking 2 or more medications for lon...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06386185 · Royal United Hospitals Bath NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 or older who have already had three specific heart tests — an echocardiogram (heart ultrasound), an ECG (heart tracing), and a right heart catheterisation (a procedure to measure pressures inside the heart) — as part of their regular medical care Who may not be ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06429579 · China National Center for Cardiovascular Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 April 2029
🇨🇳 CN

**Who might be able to join this trial:** - Children and teenagers who are older than 6 months and up to 18 years of age - Diagnosed with a specific type of pulmonary arterial hypertension (high blood pressure in the lungs) classified as "Group I" under 2022 European heart guidelines - Has already been on standard medi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06429930 · Pharmosa Biopharm Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇳🇿 NZ

**Who might be able to join this trial:** - Adults between 18 and 65 years old (inclusive) at the time of the screening visit - People with a body mass index (BMI) between 18.5 and 32.0, and who weigh at least 50 kg at screening - Non-smokers, or former smokers who have smoked no more than 100 cigarettes in their entir...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06443580 · Golden Jubilee National Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 October 2025
🇬🇧 GB

Who might be able to join this trial: - People who are currently being cared for by the Scottish Pulmonary Vascular Unit (SPVU) at the Golden Jubilee University National Hospital in Scotland. - People who have been diagnosed with any type of pulmonary hypertension (a condition involving high blood pressure in the lungs...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06454838 · Gazi University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2025
Turkey (Türkiye)

Who might be able to join this trial: **For patients:** - Children and teenagers between 6 and 18 years old who have been diagnosed with pulmonary arterial hypertension (high blood pressure in the arteries of the lungs) - People whose condition is currently stable and who are receiving standard medical treatment for t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06475781 · Foresee Pharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇹🇼 TW

**Who might be able to join this trial:** - People who have been clinically diagnosed with pulmonary hypertension associated with interstitial lung disease (PH-ILD) — a condition involving high blood pressure in the lungs combined with scarring or damage to lung tissue. - People who are willing and able to give their...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06476470 · Taichung Veterans General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2033
🇹🇼 TW

Who might be able to join this trial: - You are 18 years old or older. - You have been diagnosed with a type of lung scarring or inflammation condition (called interstitial lung disease, or ILD) by a lung specialist, a rheumatologist, or a radiologist. - Your ILD falls into one of these specific types: idiopathic pulmo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06481852 · University of Minnesota Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with pulmonary arterial hypertension (PAH) — a type of high blood pressure affecting the lungs - You have been on a stable treatment plan for PAH for at least one month before joining the study - You are able to sw...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06494878 · University of Calgary Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2030
🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇮🇪 IE🇳🇱 NL🇵🇱 PL

**Who might be able to join this trial:** - People who have been diagnosed with a specific inherited blood clotting condition before joining the trial — this includes having one copy of the Factor V Leiden gene change, one copy of the prothrombin gene change, Protein C deficiency, or Protein S deficiency. - People who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06495970 · Gradient Denervation Technologies Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇪🇸 ES

**Who might be able to join this trial:** - Your blood pressure in the arteries of your lungs (measured during a heart procedure) must be above a certain level at rest (confirm with trial site) - The resistance to blood flow through your lung arteries must be at or above a certain level at rest (confirm with trial site...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06499363 · Ferrer Internacional S.A. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2027
🇫🇷 FR

Who might be able to join this trial: - Newborn babies who received at least one dose of a medication called treprostinil (given by injection into a vein or under the skin) as part of their normal medical care within the past 5 years. - Babies who were no more than 44 weeks from the time of conception when they first s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06512935 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - Premature babies born before 34 weeks of pregnancy who had breathing difficulties at birth and are now recovering, and are currently on a breathing machine (either conventional mechanical ventilation or a type called high-frequency jet ventilation) - Babies who are older than 7 d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06526195 · Abbott Medical Devices Not Applicable · 8 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇦🇹 AT🇨🇿 CZ🇩🇰 DK🇩🇪 DE🇮🇹 IT🇳🇱 NL🇸🇦 SA🇺🇸 US

**Who might be able to join this trial:** - You have signed a consent form agreeing to take part in the study before any study procedures begin. - Your heart is pumping weakly (less than 30% of normal) and not moving enough blood through your body efficiently. - You have significant difficulty with physical activity —...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06526468 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇨🇳 CN

Who might be able to join this trial: - You are 14 years old or older - You are being assessed by doctors for a possible blood clot in the lungs (pulmonary embolism) Who may not be able to join: - You are currently pregnant - You are unwilling or unable to attend follow-up appointments - Your medical imaging scans wer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06544148 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 August 2026
🇨🇭 CH

Who might be able to join this trial: - You must be 18 years of age or older. - You must be a patient in the ICU who is on a breathing machine (ventilator) and whose doctors have already decided to use a special heart monitoring tube (called a pulmonary artery catheter) to track heart pressures and blood flow. Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06549452 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇺🇸 US

Who might be able to join this trial: - People between the ages of 10 and 21 years old - People who have been diagnosed with a specific type of pulmonary hypertension classified as either WHO Group 1 (PAH) or WHO Group 4 (CTEPH) - People whose condition falls within WHO functional class I, II, or III (meaning symptoms...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06554301 · China National Center for Cardiovascular Diseases Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are at least 18 years old. - People who are willing and able to follow the study schedule, including visits, treatments, and tests. - People diagnosed with pulmonary arterial hypertension (PAH) — a condition where blood pressure in the lungs is abnormally high — f...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06569940 · Sleepiz AG Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2024
🇨🇭 CH

Who might be able to join this trial: - You are 18 years of age or older - You are willing to sign a consent form agreeing to take part in the study - You have one or more long-term health conditions (such as diabetes, asthma, heart disease, or breathing conditions) — this applies to the patient group - You have no dia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06570473 · University of Alberta Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇦 CA

Who might be able to join this trial: - People aged 18 years or older. - People who are able to give informed consent to participate. - People who are able to follow all study procedures as required. - People who have a history of right-sided heart weakness or right heart failure caused by one of the following: a type...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06605794 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old (male or female) - Your right atrial pressure (a measurement of pressure in the right side of your heart) falls within a specific range, between 10 and 20 mmHg (confirm with trial site) - You have been diagnosed with severe idiopathic pulmo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06646653 · ResQ Medical Ltd Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 January 2027
🇮🇱 IL🇺🇸 US

**Who might be able to join this trial:** - You are a woman aged 18 or older at the time of agreeing to participate. - You are able to understand the study information and agree to take part. - You have been diagnosed with abnormal heavy bleeding from the uterus after giving birth (either vaginally or by C-section), su...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06658522 · Amsterdam UMC, location VUmc Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2026
🇳🇱 NL

**Who might be able to join this trial:** - People aged between 18 and 70 years old - People who are able to read, understand, and sign a consent form agreeing to take part - People whose pulmonary arterial hypertension (a type of high blood pressure in the lungs) affects their daily life at a moderate to severe level...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06715280 · Chinese University of Hong Kong Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 22 July 2026
Hong Kong

**Who might be able to join this trial:** - You have been diagnosed with a condition called CTEPH (a type of high blood pressure in the lungs caused by blood clots) and still have symptoms after having a procedure called Balloon Pulmonary Angioplasty (BPA) - You have been taking a stable, maximum tolerated dose of a me...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06721286 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been diagnosed with intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver) that can be surgically removed, and who meet at least one of the following: a single tumour larger than 5cm; a single tu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06735560 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 May 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have given written consent to participate. - People aged 18 or older. - People diagnosed with liver cancer (HCC) or bile duct cancer (ICC) — whether newly diagnosed or with suspected cancer that has come back, remained after treatment, or stopped responding to tre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06751082 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older - You are currently being treated with a medication called sotatercept at the Mayo Pulmonary Hypertension Clinic Who may not be able to join: - You are not able to give your own informed consent to participate in the study (for example, due to a cog...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06753981 · Qianfoshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 November 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to give their written agreement to take part in the study. - People who have pulmonary arterial hypertension (a type of high blood pressure affecting the lungs) that is not considered low-risk, and who have not yet started any treatment for this condition....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06770023 · Mayo Clinic Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - People who are already on a waiting list for a lung transplant - People who have been diagnosed with Group 1 pulmonary arterial hypertension (high blood pressure in the lungs of a specific type), confirmed by specific pressure measurements taken during a heart procedure (confirm...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06775028 · Heart Care Foundation Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 31 January 2026
🇧🇬 BG🇩🇰 DK🇮🇹 IT🇷🇴 RO🇷🇸 RS🇪🇸 ES

**Who might be able to join this trial:** - You are an outpatient (not currently admitted to hospital), of any sex, and are 65 years old or older - You have been diagnosed with atrial fibrillation (an irregular heartbeat) — whether newly diagnosed or long-standing — confirmed by a heart tracing test (ECG) or a monitor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06791668 · Ain Shams Maternity Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇪🇬 EG

Who might be able to join this trial: - Hospital records of patients who were diagnosed with a serious pregnancy complication called preeclampsia with severe features and were planned to receive a medication called magnesium sulphate. Who may not be able to join: - Records that are missing information about which type...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06804122 · Tampere Heart Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇫🇮 FI

**Who might be able to join this trial:** - Adults aged 18 or older who live in Tampere or a nearby area in Finland - People whose pulmonary arterial hypertension (a heart and lung condition) is classified as moderate in severity — specifically WHO functional class II or III (confirm with trial site) - People who are w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06832163 · Children's Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - The baby has been given inhaled nitric oxide (a gas used to help with breathing) or is expected to receive it for at least 24 hours, based on a diagnosis of a newborn lung condition called persistent pulmonary hypertension of the newborn (PPHN). - The baby has shown a positive re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06846554 · Apollo Therapeutics Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2027
🇬🇧 GB

Who might be able to join this trial: - People who are between 18 and 80 years old (inclusive) - People who have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) through a procedure called a right heart catheterisation, at any point before the screening visit - People whose pulmonary hypert...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06850792 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇧🇷 BR

**Who might be able to join this trial:** - You are 18 years of age or older and have been diagnosed with pulmonary arterial hypertension (a specific type of high blood pressure affecting the lungs, classified as "Group 1" by the World Health Organization) - You have been taking stable oral medication for your pulmonar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06852287 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with cancer of the bile ducts inside the liver (intrahepatic cholangiocarcinoma) or cancer of the gallbladder, confirmed by a tissue or cell sample - Three separate surgeons have agreed that your tumor cannot be remov...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06852924 · Novlead Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 65 years of age - People who scored between 3 and 9 points on a specific altitude sickness rating scale called the Lake Louise Acute Mountain Sickness Scale (2018 version) - People whose chest X-ray shows either thickening of the lung tissue on both sid...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06859684 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 6 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a type of bile duct cancer that starts inside the liver (intrahepatic cholangiocarcinoma), confirmed by a tissue sample, where the cancer cannot be surgically removed or has spread, and who have not yet received any treatment that works th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06862934 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇮🇹 IT

**Who might be able to join this trial:** - Your cancer has been confirmed as intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver) through a biopsy - This is either a new diagnosis or the cancer has come back at least 6 months after surgery to remove it - A specialist surgical team has determi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06865118 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇳🇴 NO

Who might be able to join this trial: - People who have been diagnosed with systemic sclerosis (SSc, also called scleroderma) according to a specific set of internationally recognised classification rules from 2013. - People who have been confirmed through heart and lung pressure testing to have pulmonary arterial hype...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06865326 · Institute of Health Information and Statistics of the Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇿 CZ

**Who might be able to join this trial:** - People who are over 18 years old - People who have signed a consent form agreeing to take part in the study and to how their personal data will be handled - People who had an episode of acute pulmonary embolism (a blood clot in the lungs) between 3 and 12 months ago and are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06871293 · Fundación Cardioinfantil Instituto de Cardiología Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇴 CO

**Who might be able to join this trial:** - You have had a confirmed COVID-19 diagnosis. - You had high blood pressure or diabetes before being registered in the study's participating hospitals or before your COVID-19 diagnosis. - You have had two or more symptoms related to long COVID that have lasted for at least 4 w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06872112 · Joseph C. Wu Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2029
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 75 years old. - People who have a certain level of physical limitation related to their condition (WHO functional class I, II, or III) even after already trying the maximum tolerated doses of 2 or more approved treatments for their condition, such as specifi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06899815 · Beijing Continent Pharmaceutical Co, Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are a healthy volunteer (the trial aims for an equal number of men and women, and if you drop out, you would be replaced by someone of the same sex) - You are between 18 and 45 years old - If you are male, you weigh at least 50kg; if you are female, you weigh at least 45...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06911632 · Tempus AI Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older at the time of signing the consent form - People who have already been diagnosed with interstitial lung disease (a group of conditions that cause scarring or inflammation in the lungs) - People whose lungs have a reduced ability to transfer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06917196 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 December 2025
🇮🇹 IT

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with a scarring lung disease, a condition that blocks the small airways in the lungs, or high blood pressure in the lung's blood vessels (pulmonary arterial hypertension), and you are being considered for or have already had a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06922240 · Suqiao Yang Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a specific type of high blood pressure in the lungs called CTEPH, and who either: could not have a surgical procedure called pulmonary endarterectomy for technical reasons; were eligible for that surgery but the r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06925516 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written informed consent to participate in the study - Adults between 18 and 75 years of age (male or female) - People whose cancer has been confirmed by laboratory testing (tissue or cell sample) to be intrahepatic cholangiocarcinoma (ICC), a type of b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06941441 · University of Washington Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with pulmonary arterial hypertension (a type of high blood pressure in the lungs) confirmed by a heart procedure called a right heart catheterization, and your diagnosis falls into one of these specific types: idiopa...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06947473 · Beijing GoBroad Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: **For Lupus Nephritis (LN):** - People aged 3 to 65 years old with lupus nephritis confirmed by a kidney biopsy (taken within 6 months before or during the screening period) showing active, proliferative disease of specific types (Type III, IV, or III/IV combined with V, excluding...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06954727 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People aged 14 years or older - People who have had a right heart catheterization (a procedure to check blood pressure inside the heart and lungs) for the first time, done because of breathlessness or a suspected condition called pulmonary hypertension (high blood pressure in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06968962 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old who weigh at least 40 kg (about 88 pounds). - People whose pulmonary arterial hypertension (a type of high blood pressure affecting the lungs) falls into a functional category rated I, II, or III by their doctor, meaning their symptoms range fr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06980584 · Beijing Chao Yang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with fibrosing mediastinitis (a condition where scar tissue forms in the chest cavity) between November 2024 and November 2026, who are between 18 and 85 years old. - People who have experienced symptoms of chest tightness, shortness of breath, and reduced abilit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06998329 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇧🇷 BR

Who might be able to join this trial: - There is a recorded or estimated date of when your first symptoms that may have been related to pulmonary arterial hypertension (a type of high blood pressure in the lungs) began. - There is a recorded date of when you were officially diagnosed with pulmonary arterial hypertensio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07013149 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇧🇷 BR

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the lungs) confirmed by a specific heart test called a right heart catheterization - People (in the "switch group") whose doctors changed t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07039604 · Pulnovo Medical (Wuxi) Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the lungs) and have undergone a specific nerve procedure called PADN since March 2024. - People who have no medical reasons that would make the PADN procedure unsafe for t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07063888 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old - You have had surgery as the main treatment for your condition - After surgery, lab tests confirmed you have a type of bile duct cancer that started inside the liver (called intrahepatic cholangiocarcinoma) - Your surgical results showed e...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07070700 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have signed a written agreement confirming you want to take part in the study. - You are 18 years old or older when you join the study. - You have been diagnosed with a type of bile duct cancer that started in the liver (intrahepatic cholangiocarcinoma) that cannot be re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07079592 · National Defense Medical Center, Taiwan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2026
🇹🇼 TW

**Who might be able to join this trial:** - You are a man or woman between 50 and 85 years old (inclusive) - You have had at least one standard heart tracing test (ECG) done within the past 3 months **Who may not be able to join:** - You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07087613 · Eko Devices, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who are willing and able to agree to take part in the study - People who have had a heart ultrasound (echocardiogram) or a heart pressure test (right heart catheterization) within 7 days before or after the study procedures Who may not be a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07099144 · Lee's Pharmaceutical Limited Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Your baby was born at 34 weeks of pregnancy or later - Your baby has breathing problems caused by low oxygen levels that have needed breathing machine support for more than 24 hours - Your baby has signs of high blood pressure in the lungs, either from a clinical assessment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07102823 · Medical University of Graz Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇦🇹 AT🇨🇭 CH🇬🇧 GB

Who might be able to join this trial: - People who have been clinically diagnosed with chronic obstructive pulmonary disease (COPD), a lung condition that makes it hard to breathe - People who have had a right heart catheterization procedure, which is a test that measures blood pressure and blood flow in the heart and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07120789 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇧🇷 BR

Who might be able to join this trial: - Adults aged 18 years or older - People who have been formally diagnosed with Group 1 Pulmonary Arterial Hypertension (PAH), which is a specific type of high blood pressure affecting the arteries in the lungs - People who are able to read and understand the language used in the st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07131241 · First Affiliated Hospital of Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 years or older - People whose heart ultrasound (echocardiogram) shows elevated pressure in the artery connecting the heart to the lungs (a reading of 35 mmHg or higher) - People who have given written agreement to take part in the study Who may not be able to join...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07132788 · University of Pennsylvania Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2029
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to give your signed agreement to take part before any study procedures begin. - You have been diagnosed with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, and it falls into one of these specific types: the cause i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07136623 · Eko Devices, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older. - People who are willing and able to give their informed consent to participate. - People who have a heart ultrasound (called a transthoracic echocardiogram) or a heart pressure test (called a right heart catheterization) scheduled or already completed wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07137260 · Simon Jäger Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) confirmed by a specific heart test called a right heart catheterization. - People whose test results at the time of joining show specific measurements of blood pressure and resistance in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07140484 · University of Alberta Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 January 2029
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older - People who have had a confirmed diagnosis of pulmonary arterial hypertension (a type of high blood pressure affecting the lungs, known as PAH Group 1) through a specific heart procedure called a right heart catheterisation, performed at any point be...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07147114 · Gachon University Gil Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2027
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 19 years or older living in South Korea - People whose heart pumps out more than 40% of blood per beat, confirmed by a heart ultrasound done within the past 12 weeks - People diagnosed with a type of heart failure (with mildly reduced or preserved pumping ability...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07149935 · RenJi Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with a specific type of high blood pressure in the lungs (pulmonary arterial hypertension), confirmed by a procedure that measures pressures inside the heart. - Your condition is classified as a mild to moderate level of severity (WHO Functional Class I, I...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07151768 · Temple University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with a chronic lung disease (such as COPD, IPF, certain types of scarring or inflammation of the lungs, or advanced sarcoidosis affecting the lungs) confirmed through chest scans and/or breathing tests, and who also have a specific...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07161908 · Institute of Health Information and Statistics of the Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇨🇿 CZ

**Who might be able to join this trial:** - Your baby was born before 32 weeks of pregnancy (premature birth) - A parent or guardian has signed the consent forms to take part in the study and to allow personal data to be used - Your baby has been diagnosed with a lung condition called bronchopulmonary dysplasia (BPD),...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07176260 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years old or older and have been diagnosed with a specific type of high blood pressure in the lungs (called pre-capillary pulmonary hypertension), confirmed by a procedure that measures pressure in the heart. - You have been diagnosed with one of three specific typ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07176962 · Yingbin Liu, MD, PhD, FACS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 March 2026
🇨🇳 CN

**Who might be able to join this trial:** *People with biliary tract cancer (internal training/validation group):* - People aged 18 to 80 who have been diagnosed with biliary tract cancer (any stage) confirmed by a pathologist, are generally well enough to carry out basic daily activities, and have blood test results...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07180368 · Xijing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 65 years or older who have been diagnosed with at least one long-term (chronic) health condition Who may not be able to join: - People who do not have any long-term (chronic) health conditions - People who have declined to take part in the study - People whose basic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07184814 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who were hospitalised at some point between 1 January 2016 and 31 December 2026. - People who have been diagnosed with a condition called Takayasu arteritis (TAK), confirmed using one or more of three recognised sets of medical diagnostic guidelines. - People whose Ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07187206 · Children's Hospital Medical Center, Cincinnati Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2032
🇺🇸 US

**Who might be able to join this trial:** - Pregnant women aged 18 or older who are able to give informed consent - Those carrying a single baby (not twins or more) - Those enrolled before 29 weeks and 6 days of pregnancy - The baby has part of the liver moved up into the chest cavity - The baby has a left-sided diaph...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07214376 · Pulnovo Medical, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 85 years old - People who have been diagnosed with chronic heart failure caused by left-sided heart disease for at least 6 months, regardless of how well their heart pumps, and who still have symptoms despite receiving the maximum recommended heart failure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07217522 · Rutgers, The State University of New Jersey Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who are currently living in the United States - People who are able to read and follow written instructions in English - People who have access to the internet and a device such as a computer, laptop, tablet, or smartphone - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07224906 · HemoCept Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - The person joining (or their legal representative) must have agreed to take part by signing a consent form before any study-related procedures begin. - Participants must be 18 years of age or older, and any gender is eligible. - Participants must be willing and able to give infor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07236970 · Alejandro Cruz Utrilla Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇪🇸 ES

Who might be able to join this trial: - You must be 18 years old or older - You must have been diagnosed with a condition called systemic sclerosis (a disease that affects the skin and internal organs) using standard medical guidelines - If you have systemic sclerosis **without** a specific type of high blood pressure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07245680 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 14 February 2029
🇫🇷 FR

Who might be able to join this trial: - People who were first diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the lungs) less than 6 months before joining the trial - People whose test results showed that their blood vessels in the lungs did not respond to vasodilator (vessel-wid...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07254078 · Irina E. Chazova Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2035
🇷🇺 RU

Who might be able to join this trial: - People who have a confirmed diagnosis of CTEPH (Chronic Thromboembolic Pulmonary Hypertension — a type of high blood pressure in the lungs caused by old blood clots) Who may not be able to join: - People whose pulmonary hypertension (high blood pressure in the lungs) is caused b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07254338 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 August 2029
🇫🇷 FR

**Who might be able to join this trial:** - You have a progressive lung disease where the lung tissue becomes scarred or stiff over time (called interstitial lung disease or lung fibrosis) - Your doctor suspects you may also have high blood pressure in the arteries of your lungs, linked to your lung disease (confirm wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07261956 · Saint Thomas Hospital, Panama Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
Panama

Who might be able to join this trial: - People who have been diagnosed with preeclampsia with severe features (a serious high blood pressure condition during pregnancy). - People who are between 24 and 41 weeks pregnant. Who may not be able to join: - People who have a long-term lung condition. - People who have a kno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07272798 · Damascus University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 November 2026
Syria

Who might be able to join this trial: - People who are having a surgical procedure called pulmonary thromboendarterectomy (a lung blood vessel surgery) for a condition known as CTEPH (a type of high blood pressure in the lungs caused by blood clots) - People who are able to read, understand, and complete a consent form...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07285655 · Liquidia Technologies, Inc. Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 1 July 2029
🇦🇹 AT🇧🇪 BE🇫🇷 FR🇩🇪 DE🇱🇻 LV🇵🇹 PT🇪🇸 ES🇬🇧 GB +1 more

Who might be able to join this trial: - You are between 18 and 80 years old. - You have been diagnosed with a lung scarring/thickening condition called ILD, confirmed by a detailed chest scan (HRCT). - A heart catheter test (a procedure that measures blood pressure inside your heart and lungs) has shown specific result...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07288398 · Tenax Therapeutics, Inc. Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇦🇷 AR🇦🇹 AT🇧🇷 BR🇧🇬 BG🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU +7 more

**Who might be able to join this trial:** - Adults between 18 and 85 years old (men or women) - People who have moderate to severe heart failure symptoms that affect their daily activities - People who have been diagnosed with a specific type of high blood pressure in the lungs linked to heart failure (called WHO Grou...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07311044 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - People attending Mayo Clinic's echocardiography laboratory for a routine, planned heart ultrasound that has been ordered for medical reasons. - People who have already had a medically ordered heart ultrasound at Mayo Clinic's echocardiography laboratory before a planned procedure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07311135 · Golden Jubilee National Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 years or older. - People who have been diagnosed with pulmonary hypertension confirmed by a right heart catheterisation procedure, showing specific pressure and resistance measurements above set thresholds. - People who are able to complete a six-minute walk te...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07312227 · Massachusetts General Hospital Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
Bolivia🇺🇸 US

Who might be able to join this trial: - Women who are giving birth at one of the participating hospitals located at high altitude (above 3,500 meters) or at sea level - You must be willing and able to sign a consent form agreeing to take part in the trial Who may not be able to join: - Women who already have certain s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07322133 · University of California, Davis Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - Babies who are more than 34 weeks and 6 days past their original due date (adjusted for prematurity) and no more than 28 days old since birth - Babies who need breathing support — such as a breathing machine, or oxygen delivered through a mask or nose tube at a certain flow rate...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07337850 · Tata Memorial Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇮🇳 IN

Who might be able to join this trial: - You are suspected to have a biliary tract cancer, specifically a type affecting the liver (called iHCC) or the gallbladder (called GBC) - You are male or female and aged 18 years or older - Your cancer is suspected to be at an advanced stage, meaning it may have spread to nearby...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07356778 · Kazuya Hosokawa Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 August 2027
🇯🇵 JP

**Who might be able to join this trial:** - You are 18 years of age or older - You have a heart condition involving an unrepaired hole or abnormal connection in the heart — specifically an ASD (a hole between the upper chambers), VSD (a hole between the lower chambers), or PDA (an abnormal blood vessel connection that...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07359599 · Ziekenhuis Oost-Limburg Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2028
🇧🇪 BE

**Who might be able to join this trial:** - People aged 18 or older - People whose pulmonary hypertension (high blood pressure in the lungs) falls into a WHO functional class between II and IV, meaning symptoms range from mild limitations during activity to severe limitations even at rest - People with iron deficiency...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07365332 · Inhibikase Therapeutics Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of pulmonary arterial hypertension (PAH) classified as WHO Group 1, specifically one of these types: idiopathic PAH (no known cause), heritable PAH (genetic), drug or toxin-induced PAH, PAH linked to a connective tissue disease, or PAH l...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07366879 · Golden Jubilee National Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇬🇧 GB

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a specific type of pulmonary hypertension (classified as Group I or non-operable Group IV) confirmed by a heart procedure called a right heart catheterisation, which showed specific pressure and resistance readings in y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07430943 · Mona Lichtblau Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇨🇭 CH

Who might be able to join this trial: - People of any sex or gender - People who are older than 18 years of age - People who have been prescribed a pulmonary rehabilitation (APR) program by a doctor and are currently taking part in that program at the University Hospital Zurich (USZ) - People who are physically and men...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07434908 · Umeå University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇸🇪 SE

Who might be able to join this trial: - Adults aged over 18 years - People who are being monitored using a PiCCO system (a device that measures heart and blood flow) during their care Who may not be able to join: - People who have been transferred from a different intensive care unit before joining the trial Importan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07453017 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇧🇷 BR

Who might be able to join this trial: - People who have been diagnosed with, or are suspected to have, a condition called pulmonary arterial hypertension (high blood pressure in the lungs), and who have been medically recommended to have a procedure that checks blood pressure inside the heart (called a right heart cath...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07457762 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 April 2026
🇧🇷 BR

Who might be able to join this trial: - You must be 18 years old or older - You must be a patient treated at the Heart Institute of the University of São Paulo Medical School's pulmonary hypertension center - You must have been diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07462260 · Sindh Institute of Cardiovascular Diseases Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2026
🇵🇰 PK

Who might be able to join this trial: - You have been diagnosed with rheumatic valvular heart disease (a heart valve problem caused by rheumatic disease) - You are between 18 and 80 years old - You have been told you have severe pulmonary hypertension (very high blood pressure in the arteries going to your lungs) Who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07477197 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2050
🇺🇸 US

**Who might be able to join this trial:** - People aged 16 or older who are suspected of having or have been diagnosed with congenital heart disease, other heart or blood vessel conditions, pulmonary hypertension (high blood pressure in the lungs), connective tissue disease, or a genetic condition. - People aged 16 or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07481981 · Insmed Incorporated Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of pulmonary arterial hypertension (PAH) — a condition causing high blood pressure in the lungs — classified as idiopathic, heritable, caused by a drug or toxin, related to a connective tissue disease, or related to a congenital h...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07495774 · Guangdong Provincial People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2032
🇨🇳 CN

Who might be able to join this trial: - Children and teenagers who were diagnosed with pulmonary hypertension (high blood pressure in the lungs) before the age of 18 - People whose pulmonary hypertension diagnosis was made according to the standard medical guidelines used at the time they joined the study - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07498244 · Medical University of Graz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2030
🇦🇹 AT

Who might be able to join this trial: - People who are undergoing a lung transplant and have been diagnosed with COPD (a chronic lung condition) or pulmonary fibrosis (scarring of the lungs), with or without also having pulmonary hypertension (high blood pressure in the lungs). - Outpatients (people receiving care with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07522203 · Istanbul Mehmet Akif Ersoy Educational and Training Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
Turkey (Türkiye)

**Who might be able to join this trial:** - People aged between 18 and 85 years - People who have been diagnosed with a condition called CTEPH (a type of high blood pressure in the lungs caused by blood clots) confirmed by a specialist team, and who have been assessed as suitable for a procedure called BPA (Balloon Pu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07529821 · Foundation University Islamabad Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2026
🇵🇰 PK

**Who might be able to join this trial:** - Your blood pressure readings are slightly above normal but not yet in the high blood pressure range (top number between 120–139 or bottom number between 80–89) - You are between 20 and 55 years old - You can be male or female - You are not currently physically active on a reg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07529834 · Foundation University Islamabad Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2026
🇵🇰 PK

**Who might be able to join this trial:** - People who have been medically diagnosed with Stage 1 high blood pressure (systolic reading of 140–159 mmHg, diastolic reading of 90–99 mmHg) or Stage 2 high blood pressure (systolic reading of 160 mmHg or higher, diastolic reading of 100 mmHg or higher), as classified by JN...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07535398 · Marmara University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
Turkey (Türkiye)

Who might be able to join this trial: - Adults between 18 and 65 years old - People who have been found to have high blood pressure in the arteries of their lungs, measured at 50 mmHg or above on a heart ultrasound (echocardiography) - People whose condition is currently stable and who are being treated and monitored b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07537517 · Hospital General Universitario Gregorio Marañon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇪🇸 ES

Who might be able to join this trial: - You must be older than 18 years of age - You have heart failure and your doctor has recommended an invasive procedure to measure how well your heart is pumping - You are willing and able to provide written consent to take part in the trial Who may not be able to join: - You do n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07556185 · The Hospital for Sick Children Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇦 CA

"Who might be able to join this trial: - You (or your child) have given consent to take part in the trial. - You are between 8 and 18 years old. - You are able to use the Medly app and its tools, such as being able to stand on a weight scale and answer questions about symptoms. - You are a patient at the Hospital for S...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07561034 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2027
🇺🇸 US

Who might be able to join this trial: - You must be a patient who receives care at the University of Rochester Medical Center Pulmonary Hypertension Clinic. - You must be an adult (over 18 years old) who has been diagnosed with pulmonary hypertension related to scarring or stiffening of the lungs, confirmed by a heart...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07563322 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 85 years old - People who have been diagnosed with a specific type of pulmonary hypertension (high blood pressure in the lungs) called Combined pre-/post-capillary PH, confirmed by specific pressure measurements taken during a heart catheter procedure (conf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07563608 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇮🇹 IT

Who might be able to join this trial: - You are between 18 and 75 years old - You have been on kidney dialysis (a machine that filters your blood) for at least 6 months, and your treatment has been consistent during that time - You attend dialysis sessions two or three times per week - You are able to read and sign a c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07576894 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with COPD, confirmed by a specific breathing test result (where the FEV1/FVC ratio is less than 0.7) - People who are 40 years of age or older **Who may not be able to join:** - People who had a COPD flare-up or worsening episode in the 3 month...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07578090 · Fu Jen Catholic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - Adults who have been diagnosed with at least one of the following conditions: high blood pressure, high blood sugar, or high cholesterol/fat levels in the blood Who may not be able to join: - People who are under 18 years of age - People who have been diagnosed with a condition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07593027 · ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years (inclusive), of any gender - People who have been diagnosed with a specific type of high blood pressure in the lungs called WHO Group 1 pulmonary arterial hypertension (PAH), confirmed by a special heart test called a right heart catheterization —...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07604805 · Guangdong Provincial People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2030
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) at the time of the screening visit. - You have been diagnosed with pulmonary arterial hypertension (PAH) — a type of high blood pressure in the lungs — specifically either the type with no known cause (idiopathic), or the type...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07613099 · National Heart, Lung, and Blood Institute (NHLBI) Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 26 May 2031
🇺🇸 US

**Who might be able to join this trial:** - You must be willing to sign and date a consent form agreeing to take part in the study - You must be willing to follow all study procedures and be available for the full length of the study - You must be 18 years old or older - You must have been diagnosed with a heart, lung,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07617376 · Wroclaw Medical University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇵🇱 PL

Who might be able to join this trial: - People who have been admitted to hospital for an urgent heart-related condition - People who are expected to be sent home within the next 48 hours after finishing their hospital treatment - People who have not yet had a flu vaccine during the current flu season Who may not be ab...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07632235 · Shanghai 6th People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with intrahepatic cholangiocarcinoma (a type of bile duct cancer that starts inside the liver), confirmed through a tissue or cell sample - People whose cancer cannot be surgically removed, has come back, or has sprea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07640048 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a type of bile duct cancer called intrahepatic cholangiocarcinoma (ICC), confirmed by a tissue biopsy, and had surgery to remove it within the past 12 weeks with the goal of curing the disease. - Your cancer has not spread to distant parts of the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07653958 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2029
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs), confirmed by a specific heart test called a right heart catheterization showing a certain pressure reading - You have at least one year's worth of medical follow-up records available Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07662655 · Xiamen Cardiovascular Hospital, Xiamen University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old - You have been diagnosed with high blood pressure in the lungs (pulmonary hypertension, confirmed by a specific heart test called right heart catheterization) at least 3 months after having a successful heart valve repair procedure called...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07667673 · Istanbul University - Cerrahpasa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
Turkey (Türkiye)

Who might be able to join this trial: - Adults who are 18 years of age or older - People who have been diagnosed with a specific type of high blood pressure in the lungs called Group 1 pulmonary arterial hypertension (PAH), based on recognised medical guidelines - People who are already being monitored or treated for P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07713914 · University of Sao Paulo General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2028
🇧🇷 BR

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the lungs), confirmed through accepted medical and test-based criteria - People who have been on a stable combination of two specific types o...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Pulmonary Hypertension. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Lung Foundation Australia extends its national lung health work to pulmonary hypertension as well.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.